Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants
- 30 August 2006
- journal article
- Published by Springer Science and Business Media LLC in Supportive Care in Cancer
- Vol. 15 (2), 213-220
- https://doi.org/10.1007/s00520-006-0125-7
Abstract
During the renovation works at our institution, the incidence density for invasive aspergillosis (IA) increased from 10 days), autologous stem cell transplantation, acute myeloblastic leukemia or relapsed acute lymphoblastic leukemia, or high-dose steroids >3 weeks. In this open-label, prospective observational study, ITC was given in ITC solution or capsule. Trough concentrations were measured in plasma with high-performance liquid chromatography after at least 7 days of treatment. Doses were adjusted to target plasma trough ITC concentrations ≥0.5 mg/l. From 2001 to 2005, 39 pediatric cancer patients received 44 prophylactic ITC cycles; 102 trough plasma concentrations were measured after oral administration. Plasma target concentrations >0.5 mg/l were achieved with both formulations. A median dose of 8 mg kg−1 day−1 (3.5–16.0 mg kg−1 day−1) was necessary in pediatric oncology patients. The bioavailability of the liquid formulation was significantly lower when the solution was given by a feeding tube. Adverse effects (gastrointestinal, elevated transaminases, and one hemolysis) which led to the cessation of the ITC prophylaxis were reported in 11% of all courses. No breakthrough infection was seen in this pediatric population. Oral ITC offers a feasible and inexpensive option for antifungal prophylaxis in selected pediatric cancer patients. Drug monitoring and meticulous consideration of possible interactions and adverse effects are mandatory.Keywords
This publication has 39 references indexed in Scilit:
- Pharmacokinetics of Proton Pump Inhibitors in ChildrenClinical Pharmacokinetics, 2005
- Early Deaths and Treatment-Related Mortality in Children Undergoing Therapy for Acute Myeloid Leukemia: Analysis of the Multicenter Clinical Trials AML-BFM 93 and AML-BFM 98Journal of Clinical Oncology, 2004
- Randomized comparison between fluconazole and itraconazole for the treatment of candidemia in a pediatric intensive care unit: A preliminary studyPediatric Critical Care Medicine, 2004
- Antifungal Agents: In Vitro Susceptibility Testing, Pharmacodynamics, and Prospects for Combination TherapyEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Positive-pressure isolation and the prevention of invasive aspergillosis. What is the evidence?Journal of Hospital Infection, 2004
- Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplantsBlood, 2004
- Role of itraconazole in haematology/oncologyArchives of Disease in Childhood, 2003
- Food-Drug InteractionsDrugs, 2002
- Intravenous Itraconazole Followed by Oral Itraconazole in the Treatment of Invasive Pulmonary Aspergillosis in Patients with Hematologic Malignancies, Chronic Granulomatous Disease, or AIDSClinical Infectious Diseases, 2001
- Aspergillosis Case-Fatality Rate: Systematic Review of the LiteratureClinical Infectious Diseases, 2001